Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | DGKA | P23743 | 2/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.49 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 3/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373410 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL10765993 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL6025493 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645269 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645279 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL11801286 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL539662 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645321 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645312 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL8190443 | 1.00 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115715221-A | Compositions and methods for treating or preventing multiple organ dysfunction syndrome | 维生宝生物股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-4087852-A1 | C-GLYCOSIDE AMINE DERIVATIVES AND METHODS OF MAKING | The United States of America, as represented by the Secretary of Agriculture (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11192913-B2 | C-glycoside amine derivatives and methods of making | The United States of America, as represented The Secretary of Agriculture (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2021141979-A1 | C-GLYCOSIDE AMINE DERIVATIVES AND METHODS OF MAKING | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2021-07-15 | — | — | WO | disclosed |
| US-20210214383-A1 | C-GLYCOSIDE AMINE DERIVATIVES AND METHODS OF MAKING | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2021-07-15 | — | — | US | disclosed |
| US-8834852-B2 | Composition for oral cavity | KAO CORPORATION (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-1797858-B1 | COMPOSITION FOR ORAL CAVITY | KAO CORP (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20100215592-A1 | Composition for oral cavity | KAO CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20080255058-A1 | Coaggregation inhibitor of Fusobacterium and cariogenic bacteria; galactose residue to prevent adhesion of plaque to teeth | KAO CORPORATION (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1797858-A1 | COMPOSITION FOR ORAL CAVITY | Kao Corporation (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-4150114-A | ENHANCED PENETRATION | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4148893-A | SUGAR ESTER AND DIALKYL SULFOXIDE ENHANCE PENETRATION THROUGH SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4148917-A | PENETRATION | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4148874-A | ENHANCE PENETRATION OF PHARMOCOLOGICALLY ACTIVE AGENTS THROUGH THE SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4148924-A | Dermatological compositions | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4148887-A | SUGAR ESTER WITH A METHYL SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4130667-A | A SUCROSE ESTER AND A PHOSPHINE OXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4130643-A | STEROID, SUCROSE ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4046886-A | SUGAR ESTER, PHOSPHINE OXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-3952099-A | MICROBIOCIDE, SUGAR ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255058-A1 | Coaggregation inhibitor of Fusobacterium and cariogenic bacteria; galactose residue to prevent adhesion of plaque to teeth | GLA, B3GAT3, B4GALT1 | MAPT 974/4885LMNA 3048/4885KDM4E 3786/4885 |
| US-20100215592-A1 | Composition for oral cavity | GLA, B3GAT3, B4GALT1 | MAPT 2004/4885LMNA 2100/4885KDM4E 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.